中药对乳腺癌新辅助化疗调节作用的研究概况  

Overview of Traditional Chinese Medicine Research on Neoadjuvant Chemotherapy Regulation for Breast Cancer

作　　者：唐镔镔[1] 蒋樱[1] 张喜平[2] 张翔[1] 欧敬民[3] 

机构地区：[1]浙江中医药大学第三临床医学院,浙江杭州310053 [2]浙江省肿瘤医院乳腺外科,浙江杭州310022 [3]上海交通大学医学院附属新华医院普外科,上海2000092

出　　处：《中华中医药学刊》2013年第8期1674-1677,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：浙江省151人才基金资助项目(2010382)

摘　　要：乳腺癌新辅助化疗是局部晚期乳腺癌的标准疗法,但由于受到不同个体对化疗反应性差异的影响,新辅助化疗往往达不到预期的效果。目前中医药协同化疗治疗该病已取得一定进展,可以提高化疗疗效,改善患者预后。通过文献查阅,从分子生物学角度出发,探讨中药对乳腺癌新辅助化疗的调节作用。Neoadjuvant chemotherapy of breast cancer is the standard therapy for locally advanced breast cancer. However, different individuals have different reactions to the chemotherapy so that neoadjuvant chemotherapy can seldom achieve the expectant effect. Up to now, traditional Chinese medicine combined with chemotherapy has made some pro- gress in treating the breast cancer. It can promote the curative effect and improve the patientrecovering. By studying the literature of science and technology, we discussed traditional Chinese medicine neoadjuvant chemotherapy for breast canc- er in term of molecular biology.

关 键 词：乳腺癌 新辅助化疗 中药 分子生物学 

分 类 号：R339.23[医药卫生—人体生理学]